CDNA vs EXAS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

CDNA

29.8
AI Score
VS
EXAS Wins

EXAS

52.3
AI Score

Investment Advisor Scores

CDNA

30score
Recommendation
AVOID NEW MONEY

EXAS

52score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric CDNA EXAS Winner
Forward P/E 156.25 243.9024 CDNA
PEG Ratio -0.12 -1.07 Tie
Revenue Growth 52.2% 23.1% CDNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 29.8/100 52.3/100 EXAS
Profit Margin 24.2% -6.4% CDNA
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD EXAS

Relative Price Performance (Last 90 Days)

CDNA 1M: +27.3% · 3M: +86.2% EXAS 1M: +1.6% · 3M: +3.2%

Current Technical Phase

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (20.4% over 20 days), RSI 64

RSI (14): 64.1 · Price: $69.16

EXAS

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.8% over 20 days), RSI 76

RSI (14): 75.9 · Price: $104.91

Fundamentals Snapshot

Metric CDNA EXAS
Market Cap — —
Forward P/E 53.6 55.8
Trailing P/E 34.0 —
Revenue (TTM) — —
Revenue Growth 0.5% 0.2%
Gross Margin 0.7% 0.7%
Operating Margin 0.0% -0.1%
EPS 2.08 -1.10
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, EXAS is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.